EMPOWERING THE FIGHT AGAINST CANCER
We are committed to improving clinical insight, speed of results, and health economics by delivering a portfolio of regulated tissue-based and liquid biopsy Next-Generation Sequencing (NGS) products to be used in laboratories worldwide.
Today, less than 20% of cancer patients receive genomic testing to inform their treatment path.
We intend to change that.
Unlock Actionable Information
from the Genome
- BIOMARKER DISCOVERY
- CDx CO-DEVELOPMENT
- CLINICAL TRIALS
- GLOBAL PATIENT ACCESS TO IVD KITS
BIOMARKER DISCOVERY
Personal Genome Diagnostics (PGDx), founded by leading researchers from Johns Hopkins University, provides advanced cancer genome analysis to help researchers and partners identify elusive cancer-related genetic changes.
- Sequence Mutations
- Copy Number Alterations
- Translocations
CDx CO-DEVELOPMENT
PGDx establishes co-development partnerships to create companion diagnostic products for personalized medicines of the future.
CLINICAL TRIALS
PGDx partners with pharmaceutical companies to help accelerate biomarker driven drug development.
GLOBAL PATIENT ACCESS TO IVD KITS
PGDx will offer tissue and liquid biopsy reagent kits with an automated bioinformatics pipeline, enabling local NGS testing in laboratories worldwide.
News
PGDx Applies CE Mark to Second Cancer Assay
Sep 25, 2019
Personal Genome Diagnostics CE Marks PGDx elio™ Tissue Complete Assay
Sep 25, 2019
